AEM1
CAS No. : 1030123-90-0
| Size | Price | Stock |
|---|---|---|
| 5mg | $60 | In-stock |
| 10mg | $105 | In-stock |
| 25mg | $220 | In-stock |
| 50mg | $340 | In-stock |
| 100mg | $540 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-113848 |
| M.Wt: | 379.41 |
| Formula: | C20H14FN3O2S |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
AEM1 is an Nrf2 inhibitor with anti-tumor and oral activity. AEM1 promotes the differentiation of HepaRG cells towards mature liver cells, aiding in the recovery of damaged liver[1][2].
In Vitro:AEM1 (0.625-10 μM, 24 h) inhibits ARE-LUC signaling and HMOX1 in A549 cells[1].
AEM1 (5 μM, 72 h) suppresses NRF2 activity in A549 cells[1].
AEM1 (0-5 μM, 24 h) causes a dose-dependent decrease in the levels of reduced glutathione (GSH) in A549 cells[1].
AEM1 (0-10 μM, 48-72 h) reduces the growth capability of A549 cells under anchorage-independent conditions, and when combined with etoposide and 5-fluorouracil, it enhances the toxicity of these two chemotherapeutic drugs on A549 cells, making them more sensitive to hydrogen peroxide-induced cell death[1].
AEM1 (1-10 μM, 24 h) inhibition of NRF2 activity is limited to cell lines where the NRF2 transcriptional program is constitutively activated due to mutations[1].
AEM1 (used at 1 μM dissolved in culture medium) inhibits NRF2 and promotes the differentiation of HepaRG cells towards mature hepatocytes[2].
In Vivo:AEM1 (50 mg/kg, oral, twice daily, 20 days) inhibits tumor proliferation in the subcutaneous A549 mouse model[1].
Pharmacokinetic Analysis in Mice[1]
| Route | Dose (mg/kg) | AUC0-24 (ng•h/mL) | t1/2 (h) | Cmax (ng/mL) |
| Oral | 20 | 453 | 2 | 176 |